Claims for Patent: 8,344,007

Summary for Patent: 8,344,007

Title:	Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents
Abstract:	A cantharimide compound may include the backbone of formula (1). R.sup.1, R.sup.2, R.sup.3, and R.sup.4 may be independently selected from the group consisting of H, C(O)OR.sup.5, C(O)R.sup.6, C(O)NR.sup.7R.sup.8, NR.sup.9C(O)R.sup.10, N--R.sup.11R.sup.12, O--R.sup.13, S--R.sup.14, P(O)(OR.sup.15)(OR.sup.16), As(O)(OR.sup.17)(OR.sup.18), SO.sub.2R.sup.19, SO.sub.3R.sup.20, and B(OR.sup.21). X.sup.1 to X.sup.4 may be independently selected from the group consisting of nitrogen and carbon, such that X.sup.1 to X.sup.4 are not all hydrogen. Y.sup.1, Y.sup.2 and R.sup.5 to R.sup.21 may be independently selected from the group consisting of hydrogen, C.sub.1-12-alkyl, -aryl, heteroaryl, and a bioactive polymer. ##STR00001##
Inventor(s):	Tang; Johnny Cheuk-on (Hong Kong, CN), Chan; Albert Sun-chi (Hong Kong, CN), Lam; Kim-hung (Hong Kong, CN), Chui; Chung-hin (Hong Kong, CN), Kok; Stanton Hon Lung (Hong Kong, CN), Yuen; Marcus Chun Wah (Hong Kong, CN), Chan; Sau Hing (Hong Kong, CN), Cheng; Chor Hing (Hong Kong, CN), Cheung; Filly (Hong Kong, CN)
Assignee:	The Hong Kong Polytechnic University (Hong Kong, CN)
Application Number:	12/428,488
Patent Claims:	1. A cantharimide compound, comprising the background of formula (1): ##STR00020## wherein, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from the group consisting of H, C(O)OR.sup.5, C(O)R.sup.6, C(O)NR.sup.7R.sup.8, NR.sup.9C(O)R.sup.10, N--R.sup.11R.sup.12, O--R.sup.13, S--R.sup.14, P(O)(OR.sup.15)(OR.sup.16), As(O)(OR.sup.17)(OR.sup.18), SO.sub.2R.sup.19, SO.sub.3R.sup.20, and B(OR.sup.21), wherein the R.sup.1 to R.sup.4 are not all hydrogen with the proviso that R.sup.3 is not hydrogen; wherein the X.sup.1 to X.sup.4 are carbon; and wherein the Y.sup.1, Y.sup.2 and R.sup.5 to R.sup.21 are independently selected from the group consisting of hydrogen, C.sub.1-12-alkyl, aryl, heteroaryl, and a bioactive polymer comprising: (i) a polymer moiety from 2 to 300 monomer units; and (ii) a terminal moiety connected to the polymer moiety at the .omega.-position, provided that the cantharimide compound is neither ##STR00021## and a pharmaceutically acceptable salt, solvate or hydrate thereof. 2. The cantharimide compound of claim 1, wherein the cantharimide compound is selected from the group consisting of ##STR00022## 3. The cantharimide compound of claim 2, wherein the cantharimide compound is ##STR00023## 4. The cantharimide compound of claim 2, wherein the cantharimide compound is ##STR00024## 5. The cantharimide compound of claim 1, wherein the polymer moiety is selected from the group consisting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols). 6. The cantharimide compound of claim 1, wherein the terminal moiety is selected from the group consisting of a propionate moiety and a butanoiate moiety. 7. The cantharimide compound according to claim 1, wherein the cantharimide compound is pegylated. 8. The cantharimide compound according to claim 7, wherein the cantharimide compound is ##STR00025## 9. A pharmaceutical composition comprising (i) a cantharimide compound comprising the background of formula (1): ##STR00026## wherein, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from the group consisting of H, C(O)OR.sup.5, C(O)R.sup.6, C(O)NR.sup.7R.sup.8, NR.sup.9C(O)R.sup.10, N--R.sup.11R.sup.12, O--R.sup.13, S--R.sup.14, P(O)(OR.sup.15)(OR.sup.16), As(O)(OR.sup.17)(OR.sup.18), SO.sub.2R.sup.19, SO.sub.3R.sup.20, and B(OR.sup.21), wherein the R.sup.1 to R.sup.4 are not all hydrogen with the proviso that R.sup.3 is not hydrogen; wherein the X.sup.1 to X.sup.4 are carbon; and wherein the Y.sup.1, Y.sup.2 and R.sup.5 to R.sup.21 are independently selected from the group consisting of hydrogen, C.sub.1-12-alkyl, aryl, heteroaryl, and a bioactive polymer comprising: (i) a polymer moiety from 2 to 300 monomer units; and (ii) a terminal moiety connected to the polymer moiety at the .omega.-position, provided that the cantharimide compound is neither ##STR00027## and a pharmaceutically acceptable salt, solvate or hydrate thereof; and (ii) a pharmaceutical acceptable carrier. 10. The pharmaceutical composition according to claim 9, wherein the cantharimide compound is selected from the group consisting of ##STR00028## 11. The pharmaceutical composition according to claim 9, wherein the cantharimide compound is ##STR00029## 12. The pharmaceutical composition according to claim 9, wherein the cantharimide compound is ##STR00030## 13. The pharmaceutical composition according to claim 9, wherein the polymer moiety is selected from the group consisting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols). 14. The pharmaceutical composition according to claim 9, wherein the terminal moiety is selected from the group consisting of a propionate moiety and a butanoiate moiety. 15. The pharmaceutical composition according to claim 9, wherein the cantharimide compound is pegylated. 16. The pharmaceutical composition according to claim 15, wherein the cantharimide compound is ##STR00031## 17. The pharmaceutical composition according to claim 9, further comprising (iii) an anti-cancer agent. 18. The pharmaceutical composition according to claim 17, wherein the anti-cancer agent is selected from the group consisting of acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bisphosphonates, pamidronate (Aredria.RTM.), sodium clondronate (Bonefos.RTM.), zoledronic acid (Zometa.RTM.), alendronate (Fosamax.RTM.), etidronate, ibandornate, cimadronate, risedromate, and tiludromate); bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin-2, interferon alpha 2a; interferon alpha 2b; interferon alpha n1; interferon alpha n3; interferon beta I a; interferon gamma I b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; anti-CD2 antibodies; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; and zorubicin hydrochloride. 19. The pharmaceutical composition according to claim 17, wherein the anti-cancer agent is selected from the group consisting of 20 epi 1,25 dihydroxyvitamin D3; 5 ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; tyrosine kinase antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti dorsalizing morphogenetic protein 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara CDP DL PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; Avastin.RTM.; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL 2; capecitabine; carboxamide amino triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro 5 azacytidine; dihydrotaxol, 9; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; HMG CoA reductase inhibitors; atorvastatin, cerivastatin, fluvastatin, lescol, lupitor, lovastatin, rosuvastatin, and simvastatin; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin like growth factor 1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; LFA-3TIP; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1 based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N acetyldinaline; N substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6 benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis acridone; prostaglandin J2; proteasome inhibitors; protein A based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; 5-fluorouracil; leucovorin; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; thalidomide; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.

Details for Patent 8,344,007

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2039-02-26
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2039-02-26
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2039-02-26
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2039-02-26
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2039-02-26